Endo Pharmaceuticals Inc. is an American pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet and Percodan. The new company was called Endo Pharmaceuticals Inc.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2012 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Endo Pharmaceuticals
Names of Lobbyists
Firm Hired Amount Endo Pharmaceuticals $4,050,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Copyright, Patent & Trademark,
- Government Issues,
- Medicare & Medicaid,
Most Frequently Disclosed Bills
Bill No. Title H.R.2632 Life Sciences Jobs and Investment Act of 2011 S.1410 Life Sciences Jobs and Investment Act of 2011 S.319 Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.3010 Regulatory Accountability Act of 2011 H.R.2 Repealing the Job-Killing Health Care Law Act H.R.1249 America Invents Act S.23 Patent Reform Act of 2011 S.27 Preserve Access to Affordable Generics Act H.R.3988 Generic Drug and Biosimilar User Fee Act of 2012 S.296 Preserving Access to Life-Saving Medications Act
RegulationsMentioned in 24 dockets; Submitted to 4 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Endo Pharmaceuticals" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Endo Pharmaceuticals
- Toggle 1 IRS Branded Prescription Drug Fee 2011
- Toggle 1 FDA Take The Actions Described in the Peitition With Respect to Endo's Discontinued Opana® ER (OxymorphoneHCI) Extended-rekease Tablets 2012
- Toggle 1 FDA Draft Guidance for Industry on Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation; Availability 2011
- Toggle 1 FDA Take Action With Respect to Endo's Crush-Resistant Formulation of Opana® (Oxymorphone HCI) Extended- Release Tablets Approved Under New Drug Application 201655 2012
Mentions in Document Text
View all mentions data for Endo Pharmaceuticals
- Toggle 11 FDA Take The Actions Described in the Peitition With Respect to Endo's Discontinued Opana® ER (OxymorphoneHCI) Extended-rekease Tablets 2012
- Toggle 5 FDA Take Action With Respect to Endo's Crush-Resistant Formulation of Opana® (Oxymorphone HCI) Extended- Release Tablets Approved Under New Drug Application 201655 2012
- Toggle 3 FDA Make a determination that Opana® ER Tablets, 7.5 mg and 15 mg were not discontinued from sale for safety or effectiveness reasons - CLOSED 2011
- Toggle 2 FDA To Determine Whether Talwin® Compound (Aspirin and Pentazocine Hydrochloride) Tablets, 325 mg/12.5 mg has Been Voluntarily Withdrawn or Withheld From Sale for Safety or Efficacy Reasons -CLOSED 2011
- Toggle 2 FDA Designate Opana® ER (oxymorphone hydrochloride) Extended-release Tablets as a Second RLD for the Purposes of Submitting an ANDA 2012
- Toggle 2 FDA Withdrawal of Approval of New Animal Drug Applications 2012
- Toggle 2 FDA Request That the Food and Drug Adminstration Make a Determination That OxyContin (Oxycodone Hydrochloride Extended-Releases) Tablets, 10 mg, 15 mg, 20 mg, 40 mg, 60 mg, 80 mg and 160 mg Withdrawn From Sale for Reasons Other Than Safety or Effectiveness 2011
- Toggle 2 FDA Abbott requests that FDA Refrain from listing a TE rating for any drug approved under § 505 (b) (2) that references AndroGel unless and until it has conducted a notice-and-comment rulemaking 2011
- Toggle 2 FDA Regulate Labeling of Opioid Analgesics 2012
- Toggle 2 FDA Take Action With Respect to Abbreviated New Drug Application Citing OxyContin (NDA 22-272) as The Reference Listed Drug -CLOSED 2012